Single-Use Technologies for the Biologic Market Size, Share, Growth, And Industry Analysis By Type (Membrane Adsorber, Bioreactors, Disposable Mixing Systems, Tangential Flow Filtration, Tubing and Connectors, Depth Filtration, Buffer Containers, Waste Containers, Single-Use Technologies for the Biologic) By Application (Monoclonal Antibodies, Vaccines, Gene Therapy, Recombinant Proteins, Blood Derivatives) and Regional Forecast From 2025 To 2033

• 

   Request a Free Sample To Get More Information on this Market

SINGLE-USE TECHNOLOGIES FOR THE BIOLOGIC MARKET REPORT OVERVIEW

The global Single-Use Technologies for the Biologic Market size is USD 5.81 billion in 2024 and is expected to reach USD 13.59 billion by 2033, growing at a compound annual growth rate (CAGR) of about 9.9% during the forecast period.

The global COVID-19 pandemic has been unprecedented and staggering, with the Single-Use Technologies for the Biologic market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to the market's growth and demand returning to pre-pandemic levels once the pandemic is over.

In the process of bioprocessing, a living source organism is transformed into a product with added value. For the system to function, the organism must be alive and responding to its environment. In light of this, it is assumed that it would adjust its physiology to achieve peak performance in reaction to even the slightest alteration in its physicochemical environment. This is consistent with the nature of system output, such as the product's capacity for variation. A bioprocess engineer's job is to comprehend and manage the production process to minimise such physiologic alterations. Sterilization, cleaning, and maintenance costs for steel-based bioreactor systems and accessories are decreased by using disposable equipment.

Also, the need for biopharmaceuticals is propelling the growth of this market. Single-use bioprocessing systems will boost production productivity while lowering initial expenditures and R&D expenses related to cleaning and validating biologic manufacturing equipment between operations. The market's expansion is anticipated to be constrained by issues including plastic waste and the extractability and leachability of bioprocessing components. Traditional bioprocessing, the creation of biologics, and the manufacture of bioproducts require steel-based bioreactors and the parts that make them up. To create contamination-free bioproducts, the majority of these products require sterilisation and related equipment, which raises manufacturers' overall investments. Yet, because sterilisation is not necessary with single-use bioprocessing systems, the need for extra expenditures is reduced. Initial investment expenses are around 40% cheaper than those of a stainless steel manufacturing of comparable scale. Between single-use and conventional operations, there are substantial differences in the sanitization and cleaning procedures. Single-use systems don't need to be cleaned because they are disposable, and the materials used to build them may be easily thrown away or burned after usage. It is significantly more energy and water efficient to switch from conventional equipment to a single-use system. Biopharmaceutical production facilities that used single-use technologies reported a 46% reduction in total water and total energy usage when compared to a stainless-steel reactor setup. Also, compared to stainless steel reactors, single-use plants have a 35% better carbon dioxide balance. These advantages are anticipated to accelerate the use of single-use bioprocessing systems during the next years.

COVID-19 IMPACT

"COVID-19 Pandemic Significantly Increased The Need For Vaccinations"

Every business and sector in the world had been severely impacted by the COVID-19 pandemic. Throughout 2020, the creation of vaccinations to prevent the coronavirus epidemic gathered steam. Many biotech and biopharmaceutical companies began creating and researching vaccinations to combat the pandemic. The COVID-19 outbreak therefore had a favourable effect on the expansion of the worldwide single-use bioprocessing business. The pharmaceutical industry's supply chain has been impacted by the COVID-19 epidemic. Many goods marketed in nations like the United States, Europe, and other nations were impacted by the limitations on pharmaceutical production and export. The health systems of nations are putting money into research and development to fight the COVID-19 epidemic quickly. The COVID-19 pandemic significantly increased the need for vaccinations. Also, this has led to an increase in disposable product demand from the biopharmaceutical industry. The single-use bioprocessing industry is expanding quickly as a result of this aspect.

LATEST TRENDS

"End User Segment For Biopharmaceutical Manufacturers Is Anticipated To Grow Rapidly Throughout The Forecast Period"

Due to factors like rising adoption of single-use technologies and systems due to the advantages, reduced initial investment and research and development costs, low cost of labour and material, and is easily disposed of, offered over conventional bioprocessing methods, rising demand for biologics, and RIS, the Biopharmaceutical Manufacturer End User Segment is anticipated to experience significant growth in the Single-use Bioprocessing Market over the forecast period.

SINGLE-USE TECHNOLOGIES FOR THE BIOLOGIC MARKET SEGMENTATION

By Type Analysis

According to type, the market can be segmented into Membrane Adsorber, Bioreactors, Disposable Mixing Systems, Tangential Flow Filtration, Tubing and Connectors, Depth Filtration, Buffer Containers, Waste Containers, Single-Use Technologies for the Biologic. Membrane Adsorber is anticipated to be the leading segment.

By Application Analysis

Based on application, the market can be divided into Monoclonal Antibodies, Vaccines, Gene Therapy, Recombinant Proteins, and Blood Derivatives. Monoclonal Antibodies will be the dominating segment.

DRIVING FACTORS

"Increasing Interest In Biopharmaceuticals Fuel the Market Growth"

According to the UN's Ageing Population Highlights, 727 million people worldwide were predicted to be 65 years of age or older in 2020; by 2050, this number is projected to quadruple to 1.5 billion people. The demand for biopharmaceuticals is anticipated to rise as the senior population grows across key markets since the aged are more sensitive to chronic illnesses and diseases. Companies increasingly favour single-use bioprocessing systems to meet the rising demand for biopharmaceuticals because they improve process efficiency and cut costs associated with labor-intensive procedures like cleaning, sterilisation, and maintenance of steel-based bioreactor systems. A wide range of biopharmaceutical applications, including as filtration, mixing, purification, upstream expression, storage, and separation, employ single-use bioprocessing technology. Hence, the market for single use bioprocessing is expanding primarily due to the rising need for biopharmaceuticals. Increased demand for customised medicine, intensive continuing development efforts, a solid product portfolio, and a wide range of applications for single-use systems are the main drivers driving the market's expansion. The adoption of single-use technology in biomanufacturing results in cheaper costs and less time being required, which is further boosting the market's expansion. The need for tailored medications has caused a sharp rise in the rate of drug development. To reduce the danger of contamination, this has boosted the demand for single-use technologies.

"Just One Usage Future Bioprocessing In Biopharmaceutical Manufacturers Is Anticipated To Grow Steadily"

Because single-use bioprocessing has several advantages over traditional bioprocessing techniques, it is predicted that biopharmaceutical producers would employ it more frequently in the future. Some advantages of these technologies include lower initial investment and R&D costs, cheap labour and material costs, and ease of disposal. Also, the manufacturer has a high adoption rate for these single-use bioprocessing units since they have a 35% more favourable CO2 balance than stainless steel reactors, which are employed in conventional bioprocessing. Merck KGaA announced an additional investment of 40 million euros in 2018 to continue its two-year effort to establish a strong production and distribution infrastructure in Asia. The development of Merck's Mobius single-use manufacturing facility in China for the production of biosimilars may be accelerated by this investment, which came after the company's announcement of a EUR-80 million life sciences investment in China in 2016. Also, the segment's expansion was supported by increased acceptance, popularity, and awareness among several manufacturers, including CMOS, OEM, and in-house manufacturers.

RESTRAINING FACTORS

"Leachable And Extractive-Related Issues Hindering The Market Growth"

There are currently no clear rules or standards governing the contamination of single-use bioprocessing systems by extractable and leachable substances. Nevertheless, the Bio-Process Systems Association has released a comprehensive set of tests that may be carried out for single-use systems (BPSA). Under demanding laboratory conditions, extractables can be extracted from source materials using the proper solvents. Leachables, on the other hand, are substances that seep into drug goods from packaging, closures, and manufacturing elements. Leachable may be thought of as a subset of extractable as a result. Certain products that are extractable and leachable are undesirable. Single-use bioprocessing goods frequently experience contamination from the container owing to leaches because they are constructed of processed plastic components. Due to their potential impacts on product quality and patient health, major concerns regarding extractable and leachable coming from the components of single-use bioprocessing systems may restrain market expansion.

• 

   Request a Free Sample To Get Analysis on Major Geographic Market

SINGLE-USE TECHNOLOGIES FOR THE BIOLOGIC MARKET REGIONAL INSIGHTS

"North American Market Contributed A Higher Percentage Of Global Revenue Than Other Regional Markets"

In terms of revenue, the North American market held the greatest market share in 2021. The expansion of the biopharmaceutical industry and the presence of substantial biopharmaceutical manufacturing facilities in the United States have contributed to the dominance of the area. Also, many contract manufacturing companies in the North American area are incorporating disposables into their business practises. Investments in this market area have grown as a result of this rising tendency. For instance, Fujifilm Diosynth invested USD 2 billion on a large cell culture manufacturing plant in the United States in January 2021. It is planned to have eight 20,000-liter bioreactors here. Moreover, Moderna Inc. received USD 483 million from the US government in April 2020 for the creation of a COVID-19 vaccine. Also, the North American government is making significant investments in the creation of COVID-19 vaccines, treatments, and diagnostic tests, which is anticipated to increase demand for single-use bioreactors and, in turn, the market as a whole. The Asia Pacific market is anticipated to expand gradually. Because to the expanding biopharmaceutical manufacturing sector, China has recently become a potential market for single-use technology. One of the most significant contract development and manufacturing companies in China, Wuxi Biologics, started conducting operations in its China site in February 2021. At this facility, there are nine 4,000-liter single-use bioreactors. The expansion of the worldwide market is anticipated to be significantly aided by the European market. Increasing R&D efforts, regional manufacturing companies with significant production facilities, and the expansion of the biopharmaceuticals industry are all contributing factors to the growth of the regional market. A significant contribution is anticipated to come from the German market because of the nation's rapidly expanding biotech industry.

KEY INDUSTRY PLAYERS

"Key Players Focus on Partnerships to Gain a Competitive Advantage "

Prominent market players are making collaborative efforts by partnering with other companies to stay ahead of the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolios.

List of Top Single-Use Technologies for the Biologic Companies

• Thermo Fisher Scientific (U.S.)
• Applikon Biotechnology (Netherlands)
• GE Healthcare (U.S.)
• Pall (U.S.)
• BioPure Technology (U.K.)
• Sartorius (Germany)
• Novasep (France)
• W. L. Gore and Associates (U.S.)
• EMD Millipore (U.S.)
• DowDuPont (U.S.)

REPORT COVERAGE

This research profiles a report with extensive studies that take into description the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, and restraints. This analysis is subject to alteration if the key players and probable analysis of market dynamics change.